Small β2-glycoprotein i peptides protect from intestinal ischemia reperfusion injury

Journal of Immunology

Volumn 189, Issue 10, 2012, Pages 5047-5056

  Pope, Michael R ^a   Bukovnik, Urska ^a   Tomich, John M ^a   Fleming, Sherry D ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN M; LEUKOTRIENE B4; PEPTIDE 296C S; PEPTIDE 305; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; ATTENUATION; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; INTESTINE ISCHEMIA; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; REPERFUSION INJURY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; INFLAMMATION; INTESTINES; MICE; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; REPERFUSION INJURY; TIME FACTORS;

EID: 84868531883     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200290     Document Type: Article

References (51)

1. Lock, G. 2001. Acute intestinal ischaemia. Best Pract. Res. Clin. Gastroenterol. 15: 83-98.
2. Crawford, M. H., F. L. Grover, W. P. Kolb, C. A. McMahan, R. A. O'Rourke, L. M. McManus, and R. N. Pinckard. 1988. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78: 1449-1458.
3. Hernandez, L. A., M. B. Grisham, B. Twohig, K. E. Arfors, J. M. Harlan, and D. N. Granger. 1987. Role of neutrophils in ischemia-reperfusion-induced mi-crovascular injury. Am. J. Physiol. 253: H699-H703.
4. Simpson, R., R. Alon, L. Kobzik, C. R. Valeri, D. Shepro, and H. B. Hechtman. 1993. Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann. Surg. 218: 444-453, discussion 453-454.
5. Rehrig, S., S. D. Fleming, J. Anderson, J. M. Guthridge, J. Rakstang, C. E. McQueen, V. M. Holers, G. C. Tsokos, and T. Shea-Donohue. 2001. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J. Immunol. 167: 5921-5927.
6. Weiser, M. R., J. P. Williams, F. D. Moore, Jr., L. Kobzik, M. Ma, H. B. Hechtman, and M. C. Carroll. 1996. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183: 2343-2348.
7. Williams, J. P., T. T. Pechet, M. R. Weiser, R. Reid, L. Kobzik, F. D. Moore, Jr., M. C. Carroll, and H. B. Hechtman. 1999. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 86: 938-942.
8. Moses, T., L. Wagner, and S. D. Fleming. 2009. TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage. J. Leukoc. Biol. 86: 971-980.
9. Madesh, M., A. Ramachandran, A. Pulimood, M. Vadranam, and K. A. Balasubramanian. 2000. Attenuation of intestinal ischemia/reperfusion injury with sodium nitroprusside: studies on mitochondrial function and lipid changes. Biochim. Biophys. Acta 1500: 204-216.
10. Ozturk, H., H. Ozturk, H. Duran, and A. K. Uzunlar. 2006. Mibefradil, a T-type Ca2+ channel blocker, protects against mesenteric ischemia-reperfusion- induced oxidative injury and histologic alterations in intestinal mucosa in rats. Dig. Dis. Sci. 51: 1454-1460.
11. Penn, A. H., and G. W. Schmid-Schönbein. 2008. The intestine as source of cytotoxic mediators in shock: free fatty acids and degradation of lipid-binding proteins. Am. J. Physiol. Heart Circ. Physiol. 294: H1779-H1792.
12. Zhang, M., W. G. Austen, Jr., I. Chiu, E. M. Alicot, R. Hung, M. Ma, N. Verna, M. Xu, H. B. Hechtman, F. D. Moore, Jr., and M. C. Carroll. 2004. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 101: 3886-3891.
13. Fleming, S. D., M. R. Pope, S. M. Hoffman, T. Moses, U. Bukovnik, J. M. Tomich, L. M. Wagner, and K. M. Woods. 2010. Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation. J. Immunol. 185: 6168-6178.
14. Fleming, S. D., and G. C. Tsokos. 2006. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun. Rev. 5: 89-92.
15. Lee, N. S., H. B. Brewer, Jr., and J. C. Osborne, Jr. 1983. beta 2-Glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. J. Biol. Chem. 258: 4765-4770.
16. Polz, E., and G. M. Kostner. 1979. The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett. 102: 183-186.
17. 2-glycoprotein I: a novel component of innate immunity. Blood 117: 6939-6947.
18. Hagihara, Y., D. P. Hong, M. Hoshino, K. Enjyoji, H. Kato, and Y. Goto. 2002. Aggregation of beta(2)-glycoprotein I induced by sodium lauryl sulfate and lysophospholipids. Biochemistry 41: 1020-1026.
19. Agar, C., G. M. van Os, M. Mörgelin, R. R. Sprenger, J. A. Marquart, R. T. Urbanus, R. H. Derksen, J. C. Meijers, and P. G. de Groot. 2010. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116: 1336-1343.
20. Kondo, A., T. Miyamoto, O. Yonekawa, A. M. Giessing, E. C. Østerlund, and O. N. Jensen. 2009. Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome. J. Proteomics 73: 123-133.
21. Ioannou, Y., J. Y. Zhang, F. H. Passam, S. Rahgozar, J. C. Qi, B. Giannakopoulos, M. Qi, P. Yu, D. M. Yu, P. J. Hogg, and S. A. Krilis. 2010. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 116: 1961-1970.
22. Passam, F. H., S. Rahgozar, M. Qi, M. J. Raftery, J. W. Wong, K. Tanaka, Y. Ioannou, J. Y. Zhang, R. Gemmell, J. C. Qi, et al. 2010. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 116: 1995-1997.
23. Passam, F. H., J. C. Qi, K. Tanaka, K. I. Matthaei, and S. A. Krilis. 2010. In vivo modulation of angiogenesis by beta 2 glycoprotein I. J. Autoimmun. 35: 232-240.
24. Sakai, T., K. Balasubramanian, S. Maiti, J. B. Halder, and A. J. Schroit. 2007. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. Am. J. Pathol. 171: 1659-1669.
25. Manfredi, A. A., P. Rovere, S. Heltai, G. Galati, G. Nebbia, A. Tincani, G. Balestrieri, and M. G. Sabbadini. 1998. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum. 41: 215-223.
26. Valesini, G., and Y. Shoenfeld. 1992. A new player in the antiphospholipid syndrome: the beta 2 glycoprotein I cofactor. Autoimmunity 14: 105-110.
27. Cabiedes, J., A. R. Cabral, and D. Alarcón-Segovia. 1995. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J. Rheumatol. 22: 1899-1906.
28. Ali, H. Y., and Z. A. Abdullah. 2008. Anti-beta(2)-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome. J. Immunotoxicol. 5: 173-177.
29. Nojima, J., Y. Masuda, Y. Iwatani, H. Kuratsune, Y. Watanabe, E. Suehisa, T. Takano, Y. Hidaka, and Y. Kanakura. 2008. Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythe-matosus. Rheumatology (Oxford) 47: 684-689.
30. Blank, M., L. Baraam, M. Eisenstein, M. Fridkin, R. Dardik, Y. Heldman, E. Katchalski-Katzir, and Y. Shoenfeld. 2011. b2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3b expression and reduces experimental-antiphospholipid-syndrome. J. Autoimmun. 37: 8-17.
31. de la Torre, Y. M., F. Pregnolato, F. D'Amelio, C. Grossi, N. Di Simone, F. Pasqualini, M. Nebuloni, P. Chen, S. Pierangeli, N. Bassani, et al. 2012. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the b2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J. Autoimmun. 38: J209-215.
32. Hunt, J., and S. Krilis. 1994. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anti-cardiolipin antibodies. J. Immunol. 152: 653-659.
33. Tomich, J. M., D. Wallace, K. Henderson, K. E. Mitchell, G. Radke, R. Brandt, C. A. Ambler, A. J. Scott, J. Grantham, L. Sullivan, and T. Iwamoto. 1998. Aqueous solubilization of transmembrane peptide sequences with retention of membrane insertion and function. Biophys. J. 74: 256-267.
34. Fleming, S. D., T. Shea-Donohue, J. M. Guthridge, L. Kulik, T. J. Waldschmidt, M. G. Gipson, G. C. Tsokos, and V. M. Holers. 2002. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 169: 2126-2133.
35. Chiu, C.-J., A. H. McArdle, R. Brown, H. J. Scott, and F. N. Gurd. 1970. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch. Surg. 101: 478-483.
36. Chen, L. W., L. Egan, Z. W. Li, F. R. Greten, M. F. Kagnoff, and M. Karin. 2003. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med. 9: 575-581.
37. Pope, M. R., S. M. Hoffman, S. Tomlinson, and S. D Fleming. 2010. Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol. Immunol. 48: 356-364.
38. Mangino, M. J., M. K. Murphy, and C. B. Anderson. 1994. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 269: 75-81.
39. Peters-Golden, M., and W. R. Henderson, Jr. 2007. Leukotrienes. N. Engl. J. Med. 357: 1841-1854.
40. Welch, B. D., J. N. Francis, J. S. Redman, S. Paul, M. T. Weinstock, J. D. Reeves, Y. S. Lie, F. G. Whitby, D. M. Eckert, C. P. Hill, et al. 2010. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84: 11235-11244.
41. Welch, B. D., A. P. VanDemark, A. Heroux, C. P. Hill, and M. S. Kay. 2007. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA 104: 16828-16833.
42. Liu, M., C. Li, M. Pazgier, C. Li, Y. Mao, Y. Lv, B. Gu, G. Wei, W. Yuan, C. Zhan, et al. 2010. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc. Natl. Acad. Sci. USA 107: 14321-14326.
43. Ruiz-Irastorza, G., M. A. Khamashta, and G. R. Hughes. 2002. Hughes syndrome crosses boundaries. Autoimmun. Rev. 1: 43-48.
44. Khamashta, M. A., and G. R. Hughes. 2004. The clinical aspects of the anti-phospholipid syndrome. In Systemic Lupus Erythematosus. R. G. Lahita, ed. San Diego, CA, Academic Press p. 1107-1123.
45. Katzav, A., A. Faust-Socher, F. Kvapil, D. M. Michaelson, M. Blank, C. G. Pick, Y. Shoenfeld, A. D. Korczyn, and J. Chapman. 2011. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol. Aging 32: 272-279.
46. Zhang, M., and M. C. Carroll. 2007. Natural IgM-mediated innate autoimmu-nity: a new target for early intervention of ischemia-reperfusion injury. Expert Opin. Biol. Ther. 7: 1575-1582.
47. Zhang, M., E. M. Alicot, I. Chiu, J. Li, N. Verna, T. Vorup-Jensen, B. Kessler, M. Shimaoka, R. Chan, D. Friend, et al. 2006. Identification of the target self-antigens in reperfusion injury. J. Exp. Med. 203: 141-152.
48. Haas, M. S., E. M. Alicot, F. Schuerpf, I. Chiu, J. Li, F. D. Moore, and M. C. Carroll. 2010. Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc. Res. 87: 618-627.
49. Alard, J. E., F. Gaillard, C. Daridon, Y. Shoenfeld, C. Jamin, and P. Youinou. 2010. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J. Immunol. 185: 1550-1557.
50. Meroni, P. L., E. Raschi, C. Testoni, A. Parisio, and M. O. Borghi. 2004. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in en-dothelial cell activation by antiphospholipid antibodies. Autoimmun. Rev. 3: 510-515.
51. Allen, K. L., F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, and K. R. McCrae. 2012. A novel pathway for human endothelial cell activation by anti-phospholipid/anti-b2 glycoprotein I antibodies. Blood 119: 884-893.